Cardiovascular Medicine: New Therapeutic Drugs Approved by the US FDA (2013?2017) - Li, Y. Robert
136,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Written in an accessible style and consistent format, "Cardiovascular Medicine: New Therapeutic Drugs Approved by the US FDA (2013-2017)" takes a unique approach to integrating the fundamental concepts with high quality cutting-edge research discoveries and translating essential bioscience to evidence-based clinical medicine so as to provide the reader a comprehensive picture of this rapidly evolving field in a concise manner. Blends basic and clinical sciences needed to effectively demonstrate the importance of the field Includes full-color illustrations to facilitate the understanding of the…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Written in an accessible style and consistent format, "Cardiovascular Medicine: New Therapeutic Drugs Approved by the US FDA (2013-2017)" takes a unique approach to integrating the fundamental concepts with high quality cutting-edge research discoveries and translating essential bioscience to evidence-based clinical medicine so as to provide the reader a comprehensive picture of this rapidly evolving field in a concise manner. Blends basic and clinical sciences needed to effectively demonstrate the importance of the field Includes full-color illustrations to facilitate the understanding of the essential concepts Cites references mostly from highly influential journals to ensure the top quality of the information Uses chapter highlights and self-assessment questions to enhance the assimilation of the cutting-edge knowledge Serves as a valuable reference or textbook for students, faculty, clinicians, and other health professionals in the fields of biomedical science, pharmacology, pharmacotherapeutics, and clinical medicine
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Y. Robert Li, MD, MPH, PhD, is Professor and Chair of Pharmacology at Campbell Medical School and Adjunct Professor at several other major universities, including Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Department of Biomedical Sciences and Pathobiology of Virginia Polytechnic Institute and State University, and Department of Biology of University of North Carolina at Greensboro. He is an internationally recognized expert in free radical and cardiovascular research. Y. Robert Li is also Co-Editor-in-Chief of Toxicology Letters, a well-respected international journal published by Elsevier and editorial board member for a number of major scholarly journals. He is author of over 130 peer-reviewed journal articles and his research has been funded extensively by the United States National Institutes of Health. Other recent books of Y. Robert Li include the widely adopted "Free Radical Biomedicine: Principles, Clinical Correlations, and Methodologies"; "Antioxidants in Biology and Medicine: Essentials, Advances, and Clinical Applications"; "Cardiovascular Diseases: From Molecular Pharmacology to Evidence-Based Therapeutics"; "Biomedical Research: Strategic Planning for Success", and "Essentials of Free Radical Biology and Medicine".